<DOC>
	<DOC>NCT01280175</DOC>
	<brief_summary>The purpose of this study is to evaluate the systemic exposure of BDP, its metabolite beclomethasone 17-monopropionate (B17MP) and formoterol after inhalation of BDP/Formoterol 100/6 µg pMDI combination (CHF1535) using the standard actuator and charcoal block technique or using a Spacer (AeroChamber Plus, Trudell) in comparison with inhalation using the standard actuator</brief_summary>
	<brief_title>Foster With or Without Charcoal Block or Aerochamber Plus</brief_title>
	<detailed_description />
	<mesh_term>Charcoal</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Sex: male 18≤age≤45 years old BMI: 18≤BMI≤28 kg/m2 Nonsmokers Vital signs: SBP 100139 mmHg, DBP 5089, HR 5090 bpm, measured after 5 min of rest in the sitting position Full comprehension: ability to use correctly the pMDI preparations; ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the Investigator and to comply with the requirements of the entire study Informed Consent: signed written informed consent prior to inclusion in the study. ECG (12 leads): clinically relevant abnormalities and/or QTc &gt;450 msec; Physical findings: clinically relevant abnormal physical findings, which could interfere with the objectives of the study; in particular any abnormality in the lung functionality: FEV1 &lt;80% predicted values according to European Respiratory Society basing upon Quanjer et al. (25) Laboratory analyses: clinically relevant abnormal laboratory values indicative of physical illness; in particular positive HIV1 and HIV2 serology and/or positive hepatitis serology indicating acute or chronic hepatitis B or C Allergy: ascertained or presumptive hypersensitivity to the active principles and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study Diseases: relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases, that may interfere with the aim of the study Medications: medication, including OTC, during 2 weeks before the start of the study. Any known enzyme inducing drug or enzyme inhibitor must be stopped at least 2 months before study start Investigative drug trials: participation in the evaluation of any drug within 3 months prior to the screening Blood donation: blood donations during the 3 months prior to this study Drug, alcohol, caffeine, tobacco: history of drug, alcohol [&gt;2 drinks/day, defined according to USDA Dietary Guidelines 2005 (26)], caffeine (&gt;5 cups coffee/tea/day) abuse or smoking Abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits within the past 4 weeks.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>BDP</keyword>
	<keyword>Formoterol</keyword>
	<keyword>pMDI</keyword>
	<keyword>Aerochamber Plus</keyword>
	<keyword>Charcoal</keyword>
</DOC>